UNSPSC 51171631: Macrogol or polyethylene glycol

This classification denotes a synthetic polymer with the molecular formula C2H6O2(C2H4O)N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B697894SGQ. European Medicines Agency schedules polyethylene glycol 400 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16380MIG. The term polyethylene glycol 400 is an International Nomenclature of Cosmetic Ingredients designation.

European Medicines Agency schedules polyethylene glycol 400 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16380MIG. Macrogol or polyethylene glycol bears US NLM identifiers UMLS ID C0032483 and NCI Concept Code C762. SMILES: COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO.

UNSPSC 51171631 Macrogol or polyethylene glycol is a Commodity code covering chemical compounds used in pharmaceutical and clinical applications. State and local procurement under this code reflects demand for polyethylene glycol products in two distinct contexts: as a drug-testing specimen collection and processing reagent in criminal justice supervision, and as an active pharmaceutical ingredient or formulation excipient in generic pharmaceutical supply programs serving state employee health plans and institutional facilities. The issuing bodies span state health and human services departments, county criminal justice agencies, and multistate cooperative purchasing alliances administering contracts for multiple participating jurisdictions.

Recent activity centers on Texas and Minnesota. The Collin County Community Supervision and Corrections Department (Texas) issued RFP 2026-327 on July 9, 2026, with proposals due July 23, 2026, for offender specimen collection and drug testing services—a contract estimated at $600,000 annually for two years with three optional one-year renewals. The Texas Health and Human Services Commission posted RFI HHS0017013 in late March 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, a market-intelligence phase informing future formal solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon. The MMCAP procurement emphasizes price competitiveness (weighted at 75 percent) and requires vendor compliance with FDA cGMP and Drug Supply Chain Security Act standards, distribution through three authorized wholesalers, and a two-year initial contract term.